[{"id":"fdfd9de7-291d-41f6-a1e7-37009f68c58e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665739","created_at":"2021-01-19T20:43:36.156Z","updated_at":"2025-02-25T14:15:45.821Z","phase":"Phase 2","brief_title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","source_id_and_acronym":"NCT04665739","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • everolimus • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 02/03/2023","start_date":" 02/03/2023","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-17"},{"id":"13a8ea63-40e9-404c-b670-688e9b2c8b54","acronym":"LuDO-N","url":"https://clinicaltrials.gov/study/NCT04903899","created_at":"2021-05-27T13:53:06.417Z","updated_at":"2025-02-25T15:26:53.866Z","phase":"Phase 2","brief_title":"177Lutetium-DOTATATE in Children with Primary Refractory or Relapsed High-risk Neuroblastoma","source_id_and_acronym":"NCT04903899 - LuDO-N","lead_sponsor":"Jakob Stenman","biomarkers":" SSTR • CD34 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR Expression","tags":["SSTR • CD34 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/19/2021","start_date":" 05/19/2021","primary_txt":" Primary completion: 05/20/2026","primary_completion_date":" 05/20/2026","study_txt":" Completion: 05/20/2031","study_completion_date":" 05/20/2031","last_update_posted":"2025-02-11"},{"id":"11c83591-4e3f-4858-aa5c-0d9de1fd1c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691465","created_at":"2023-01-20T16:00:13.319Z","updated_at":"2025-02-25T16:54:41.696Z","phase":"Phase 2","brief_title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","source_id_and_acronym":"NCT05691465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • RB1 • SYP • CHGA","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • SYP • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/27/2023","start_date":" 12/27/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-04"},{"id":"77bffc42-2b22-4b22-8139-b83130b4cbfe","acronym":"COMPOSE","url":"https://clinicaltrials.gov/study/NCT04919226","created_at":"2021-06-10T01:52:29.850Z","updated_at":"2025-02-25T17:37:09.573Z","phase":"Phase 3","brief_title":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","source_id_and_acronym":"NCT04919226 - COMPOSE","lead_sponsor":"ITM Solucin GmbH","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-01-29"},{"id":"08d03f09-1c0e-4f63-9272-84ef1303882d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04529044","created_at":"2021-01-18T21:41:11.607Z","updated_at":"2025-02-25T15:44:08.465Z","phase":"Phase 2","brief_title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","source_id_and_acronym":"NCT04529044","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1 • CDK4 • SSTR","pipe":"","alterations":" ","tags":["PD-L1 • CDK4 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2024-12-20"},{"id":"788d5186-c5e0-4cdd-ba52-51d8b5d8095b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04544098","created_at":"2021-02-11T16:55:22.383Z","updated_at":"2024-07-02T16:35:06.529Z","phase":"Phase 1","brief_title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","source_id_and_acronym":"NCT04544098","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 09/02/2020","start_date":" 09/02/2020","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-05-02"},{"id":"0e0834be-0c1a-4cc9-89e5-a3e0950833c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04082520","created_at":"2021-02-11T16:54:03.522Z","updated_at":"2024-07-02T16:35:12.274Z","phase":"Phase 2","brief_title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","source_id_and_acronym":"NCT04082520","lead_sponsor":"Mayo Clinic","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 04/08/2020","start_date":" 04/08/2020","primary_txt":" Primary completion: 09/04/2024","primary_completion_date":" 09/04/2024","study_txt":" Completion: 09/04/2025","study_completion_date":" 09/04/2025","last_update_posted":"2024-03-29"},{"id":"35e34361-ae0b-4c69-8d47-4171b1f9736a","acronym":"PROMENADE","url":"https://clinicaltrials.gov/study/NCT04997317","created_at":"2021-08-09T13:53:17.457Z","updated_at":"2024-07-02T16:35:15.190Z","phase":"Phase 1","brief_title":"Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide","source_id_and_acronym":"NCT04997317 - PROMENADE","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-12"},{"id":"45acda49-4eea-4ad8-bb32-a2e6799876f3","acronym":"START-NET","url":"https://clinicaltrials.gov/study/NCT05387603","created_at":"2022-05-24T12:54:25.088Z","updated_at":"2024-07-02T16:35:15.531Z","phase":"Phase 3","brief_title":"Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.","source_id_and_acronym":"NCT05387603 - START-NET","lead_sponsor":"Lund University Hospital","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2024-03-08"},{"id":"abe95a5f-8246-429d-92a8-a73471011fbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01876771","created_at":"2021-01-18T08:24:57.554Z","updated_at":"2024-07-02T16:35:21.860Z","phase":"Phase 2","brief_title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","source_id_and_acronym":"NCT01876771","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR positive","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 04/29/2014","start_date":" 04/29/2014","primary_txt":" Primary completion: 12/01/2033","primary_completion_date":" 12/01/2033","study_txt":" Completion: 12/01/2033","study_completion_date":" 12/01/2033","last_update_posted":"2024-01-30"},{"id":"01ee014a-7d08-4da3-a0a3-f28ad90c284a","acronym":"COMPETE","url":"https://clinicaltrials.gov/study/NCT03049189","created_at":"2021-01-18T15:00:56.649Z","updated_at":"2024-07-02T16:35:27.442Z","phase":"Phase 3","brief_title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","source_id_and_acronym":"NCT03049189 - COMPETE","lead_sponsor":"ITM Solucin GmbH","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 309","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2023-11-30"},{"id":"655df006-f3b7-40a3-bc87-b9058d866bb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03457948","created_at":"2021-01-19T15:39:53.519Z","updated_at":"2025-02-25T16:07:39.992Z","phase":"Phase 2","brief_title":"Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases","source_id_and_acronym":"NCT03457948","lead_sponsor":"Nicholas Fidelman, MD","biomarkers":" PD-L1 • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["PD-L1 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2023-11-17"},{"id":"d35bf2f8-c72c-4e41-b03f-2a4b88237830","acronym":"LuPARP","url":"https://clinicaltrials.gov/study/NCT04375267","created_at":"2021-01-18T21:08:12.416Z","updated_at":"2025-02-25T15:43:58.882Z","phase":"Phase 1","brief_title":"177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours","source_id_and_acronym":"NCT04375267 - LuPARP","lead_sponsor":"Vastra Gotaland Region","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/23/2020","start_date":" 04/23/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-11-14"},{"id":"3570464a-977a-4c4b-b9ce-da03668a6a6f","acronym":"LEVEL","url":"https://clinicaltrials.gov/study/NCT05918302","created_at":"2023-06-26T14:09:09.001Z","updated_at":"2024-07-02T16:35:30.525Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.","source_id_and_acronym":"NCT05918302 - LEVEL","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 03/01/2028","primary_completion_date":" 03/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2023-11-02"},{"id":"4401c394-5d2d-4472-8e80-7bc5059b71df","acronym":"LUFOR","url":"https://clinicaltrials.gov/study/NCT06045260","created_at":"2023-09-21T15:10:50.581Z","updated_at":"2024-07-02T16:35:36.405Z","phase":"Phase 2","brief_title":"\"Receptor Radionuclide Therapy With 177Lu-DOTATOC","source_id_and_acronym":"NCT06045260 - LUFOR","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Solucin (177Lu-edotreotide)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-09-21"},{"id":"0d0d15de-eb4a-4e35-9e1e-388c588b5f9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03971461","created_at":"2021-01-18T19:32:12.909Z","updated_at":"2024-07-02T16:35:40.851Z","phase":"Phase 2","brief_title":"Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","source_id_and_acronym":"NCT03971461","lead_sponsor":"NYU Langone Health","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-08-04"},{"id":"37969cd9-a62c-4486-b4a3-d4e0ab0714cd","acronym":"P-PRRT","url":"https://clinicaltrials.gov/study/NCT02754297","created_at":"2021-01-18T13:30:07.753Z","updated_at":"2024-07-02T16:35:46.711Z","phase":"Phase 2","brief_title":"Personalized PRRT of Neuroendocrine Tumors","source_id_and_acronym":"NCT02754297 - P-PRRT","lead_sponsor":"CHU de Quebec-Universite Laval","biomarkers":" SSTR • CHGA","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 04/12/2016","start_date":" 04/12/2016","primary_txt":" Primary completion: 04/12/2025","primary_completion_date":" 04/12/2025","study_txt":" Completion: 04/12/2029","study_completion_date":" 04/12/2029","last_update_posted":"2023-06-01"},{"id":"0ae73cff-61c0-41a6-852a-74840ce5f7a8","acronym":"Radio-Marker","url":"https://clinicaltrials.gov/study/NCT05513469","created_at":"2022-08-24T21:07:36.463Z","updated_at":"2024-07-02T16:35:51.102Z","phase":"","brief_title":"Biomarker Identification of Radionuclide Therapy-induced Radiation Responses","source_id_and_acronym":"NCT05513469 - Radio-Marker","lead_sponsor":"Erasmus Medical Center","biomarkers":" TP53BP1","pipe":"","alterations":" ","tags":["TP53BP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-04-07"},{"id":"a5b1010b-0b46-4d40-9406-0f7ebc1fac41","acronym":"","url":"https://clinicaltrials.gov/study/NCT01237457","created_at":"2021-02-11T16:52:30.267Z","updated_at":"2024-07-02T16:35:52.906Z","phase":"Phase 2","brief_title":"177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms","source_id_and_acronym":"NCT01237457","lead_sponsor":"Ebrahim S Delpassand","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Completed","enrollment":" Enrollment 143","initiation":"Initiation: 10/27/2010","start_date":" 10/27/2010","primary_txt":" Primary completion: 11/17/2016","primary_completion_date":" 11/17/2016","study_txt":" Completion: 07/25/2017","study_completion_date":" 07/25/2017","last_update_posted":"2023-03-20"},{"id":"408ec697-317c-432e-9870-e974167b3c92","acronym":"PUTNET","url":"https://clinicaltrials.gov/study/NCT04276597","created_at":"2021-01-18T20:46:10.712Z","updated_at":"2024-07-02T16:35:53.562Z","phase":"Phase 2","brief_title":"Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.","source_id_and_acronym":"NCT04276597 - PUTNET","lead_sponsor":"Excel Diagnostics and Nuclear Oncology Center","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Solucin (177Lu-edotreotide)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2023-03-10"},{"id":"9bfec321-b7bc-47c7-9fb1-8bf0511e4140","acronym":"","url":"https://clinicaltrials.gov/study/NCT01842165","created_at":"2021-01-18T08:12:35.783Z","updated_at":"2024-07-02T16:36:00.646Z","phase":"Phase 3","brief_title":"177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs","source_id_and_acronym":"NCT01842165","lead_sponsor":"Jules Bordet Institute","biomarkers":" SSTR • CHGA","pipe":"","alterations":" ","tags":["SSTR • CHGA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 05/01/2013","start_date":" 05/01/2013","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 09/19/2022","study_completion_date":" 09/19/2022","last_update_posted":"2022-11-10"},{"id":"81498a4c-038d-488e-857c-348cb81a2810","acronym":"","url":"https://clinicaltrials.gov/study/NCT03478358","created_at":"2021-02-11T16:53:34.239Z","updated_at":"2024-07-02T16:36:04.680Z","phase":"Phase 1","brief_title":"Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors","source_id_and_acronym":"NCT03478358","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate) • 177Lu-EBTATE • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/30/2017","start_date":" 04/30/2017","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2022-08-31"},{"id":"40cb9e42-522f-4b09-a43f-5ddcdc4dd14f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04525638","created_at":"2021-01-18T21:40:28.414Z","updated_at":"2024-07-02T16:36:06.233Z","phase":"Phase 2","brief_title":"A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours","source_id_and_acronym":"NCT04525638","lead_sponsor":"Fundación de investigación HM","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2022-08-02"},{"id":"2c505dcd-09e5-4284-9e05-a7a8505e815b","acronym":"FENET-2016","url":"https://clinicaltrials.gov/study/NCT04790708","created_at":"2021-03-10T12:54:51.502Z","updated_at":"2024-07-02T16:36:33.460Z","phase":"","brief_title":"Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)","source_id_and_acronym":"NCT04790708 - FENET-2016","lead_sponsor":"University Hospital of Ferrara","biomarkers":" mTOR • SSTR • UBR5","pipe":" | ","alterations":" SSTR Expression","tags":["mTOR • SSTR • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Solucin (177Lu-edotreotide)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 06/30/2023","primary_completion_date":" 06/30/2023","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2021-03-10"}]